

CURRICULUM VITAE

ISABELLE BOUTRON

MD, PhD

Update 01-2023

Personal data

Isabelle Boutron (MD, PhD)

METHODS team, Centre of Research in Epidemiology and Statistics (CRESS), INSERM UMR-1153, Université Paris Cité Hôtel Dieu Hospital

1 place du Parvis Notre Dame, 75004 PARIS, France

tel 33 (0)1 42.34.78.33

fax 33 (0)1 42.34.87.90

e-mail : isabelle.boutron@aphp.fr

Date of birth: February 14th, 1971

ORCID ID <https://orcid.org/0000-0002-5263-6241>

Position

2019-present: Director of Cochrane France

2019-present: Head of the METHODS team within the Centre of Epidemiology and Statistics (CRESS-UMR1153)

2019-present: Deputy director of the doctoral School in Public Health, Université Paris Cité

2014-present: Deputy director of the French EQUATOR (Enhancing the QUALity and Transparency Of health Research) centre.

2012-present: Professor of Epidemiology in the Centre of Clinical Epidemiology, Hôtel Dieu Hospital, University Paris Cité.

2020-present: PI of the Covid-nma initiative (<https://covid-nma.com/>), an international initiative working in conjunction with the World Health Organization (WHO) to provide a living mapping and living systematic review of interventions for treating and preventing COVID-19.

2016-2020: PI of the MIROR project which is an innovative and ambitious joint doctoral training programme funded by Marie Skłodowska-Curie Actions, dedicated to Methods in Research on Research (MIROR) in the field of clinical research (<http://miror-ejd.eu/>).

2015-2019: Deputy director of Cochrane France.

2012-2018: Elected member of the Cochrane Methods Executive

2010-present: Co-convenor of the Bias Methods group, Cochrane

2009-2012: Associate Professor of Epidemiology in the Centre of Clinical Epidemiology, Hôtel Dieu Hospital, University Paris Descartes

2008-09: Postdoctoral fellowship in the Centre for Statistics in Medicine, Pr Altman, Oxford University

2004-2008: Assistant Professor in Epidemiology in the Bichat Hospital, University Paris Diderot

Education and qualifications

- **2011:** Accreditation to supervise research (HDR – University Paris Descartes, Paris, France)
- **2006:** Ph.D. in Clinical Epidemiology. Thesis subject: Methodology in assessing nonpharmacological treatments, INSERM U738, University Pierre et Marie Curie
- **2002:** M.D., University Pierre et Marie Curie

Academic awards and honours

- Awards Louis-Daniel Beauperthuy, Académie des sciences (2014)
- Awards of scientific excellence (2010-2014)
- Post doctoral fellowship grant

Teaching and responsibilities

- Deputy director of the doctoral school of Public Health, Université Paris Cité
- Responsible for the programme LAS of Public Health dedicated to medical student at Université Paris Cité
- Responsible of the international Master programme: “Comparative Effectiveness Research”, Université Paris Cité

Students’ supervision

- Supervision of 29 master students since 2003 (18 published their work as first author in a peer-reviewed journal)
- Supervision or co-supervision of 12 graduated PhD students
- Current supervision of 3 PhD students

International relations

- Member of the CONSORT steering committee since 2018 which became the CONSORT-SPIRIT steering committee in 2019
- Co-lead of the CONSORT (Consolidated Standards of Reporting Trials) for Non-Pharmacological Treatment, Paris (meeting organized in Paris 2006, and 2014)
- Writing committee of the Waste in research group that published 5 articles in the Lancet in January 2014 dedicated to waste in research
- International collaborations with Oxford university (Dr Hopewell), Ottawa university (Pr Moher), The Nordic Cochrane Centre (Dr Hróbjartsson), McGill university (Pr Thombs), York university (Pr. Torgerson), Bond University (Pr Glasziou)

Editorial responsibilities

- Academic Editor for Plos Biology, BMC Medicine
- Former senior editor for Trials
- Former academic editor for Plos Medicine, Plos One, BMC Medical Research Methodology
- Reviewer for JAMA, BMJ, Annals of Internal Medicine, Nature Medicine, Nature communication, J clin Epidemiology

Recent fundings obtained as PI

- **2020:** Agence Nationale de la Recherche COVID-NMA Initiative
Funding : 250 000 euros
- **2015:** H2020-MSCA-ITN-2015 - Innovative Training Network- European Joint Doctorates (ITN-EJD) funded by Marie Skłodowska-Curie Actions.
Title: Methods in Research on Research (MIROR) (<http://miror-ejd.eu>)
Consortium: 7 world-class research teams (University of Paris Descartes, Amsterdam, Liverpool, Ghent, Split, Universitat Politècnica de Catalunya, CNRS); 6 non-academic partners (BioMed Central, BMJ,

Cochrane, ECRIN, NICE, Sideview) and 4 major academic partners (University of Oxford - EQUATOR network, Ottawa Hospital Research Institute, Meta-Research Innovation Center at Stanford University).
Funding: 3,800,000 euros

- **2018**: National Cancer Institute (INCa – France, Paris).

Title: Development and validation of a tool to assess the burden of research for participants of cancer randomized controlled trials.

Funding: 200 000 euros

Scientific production

More than 200 citations on PubMed including

- 140 publications in 1st, 2nd or last author.
- 20 publications in the top 6 of the best generalist newspapers in 1st, 2nd, last author.
- 3 articles in 1st or 2nd author in the top 1% of the most cited articles.
- H index: 54

10 best publications

1. Nguyen C, Boutron I, Zegarra-Parodi R, Baron G, Alami S, Sanchez K, Daste C, Boisson M, Fabre L, Krief P, Krief G, Lefèvre-Colau MM, Rannou F. Effect of Osteopathic Manipulative Treatment vs Sham Treatment on Activity Limitations in Patients With Nonspecific Subacute and Chronic Low Back Pain: A Randomized Clinical Trial. **JAMA Intern Med.** 2021;181(5):620-30.
2. Nguyen VT, Engleton M, Davison M, Ravaud P, Porcher R, Boutron I. Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. **BMC Med.** 2021;19(1):279.
3. Boutron I, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D, Rada G, Tovey D, Grasselli G, Ravaud P. The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. **Ann Intern Med.** 2020;173(12):1015-7.
4. Naidoo N, Nguyen VT, Ravaud P, Young B, Amiel P, Schanté D, Clarke M, Boutron I. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. **BMC Med.** 2020;18(1):6.
5. Boutron I, Haneef R, Yavchitz A, Baron G, Novack J, Oransky I, Schwitzer G, Ravaud P. Three randomized controlled trials evaluating the impact of "spin" in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit. **BMC Med.** 2019;17(1):105.
6. Boutron I, Ravaud P. Misrepresentation and distortion of research in biomedical literature. **Proc Natl Acad Sci U S A.** 2018;115(11):2613-9.
7. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. **Ann Intern Med.** 2017 Jul 4;167(1):40-47.
8. Moher D, Glasziou P, Chalmers I, (...), Boutron I. Increasing value and reducing waste in biomedical research: who's listening? **Lancet.** 2016;387(10027):1573-86.
9. Boutron I, Dechartres A, Baron G, Li J, Ravaud P. Sharing of Data From Industry-Funded Registered Clinical Trials. **JAMA.** 2016;315(24):2729-30.

Publications (including research letters)

2022

1. Charvet C, **Boutron I**, Morvan Y, Le Berre C, Touboul S, Gaillard R, Fried E, Chevance A. How to measure mental pain: a systematic review assessing measures of mental pain. *Evid Based Ment Health*. 2022;25(4):e4.
2. Davidson M, Menon S, Chaimani A, Evrenoglou T, Ghosn L, Graña C, Henschke N, Cogo E, Villanueva G, Ferrand G, Riveros C, Bonnet H, Kapp P, Moran C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, **Boutron I**. Interleukin-1 blocking agents for treating COVID-19. *The Cochrane database of systematic reviews*. 2022;1(1):Cd015308.
3. Egnell M, **Boutron I**, Péneau S, Ducrot P, Touvier M, Galan P, Fezeu L, Porcher R, Ravaud P, Hercberg S, Kesse-Guyot E, Julia C. Impact of the Nutri-Score front-of-pack nutrition label on purchasing intentions of individuals with chronic diseases: results of a randomised trial. *BMJ open*. 2022;12(8):e058139.
4. El Mikati IK, Khabsa J, Harb T, Khamis M, Agarwal A, Pardo-Hernandez H, Farran S, Khamis AM, El Zein O, El-Khoury R, Schünemann HJ, Akl EA, Alonso-Coello P, Alper BS, Amer YS, Arayssi T, Barker JM, Bouakl I, **Boutron I**, Brignardello-Petersen R, Carandang K, Chang S, Chen Y, Cuker A, El-Jardali F, Florez I, Ford N, Grove J, Guyatt GH, Hazlewood GS, Kredo T, Lamontagne F, Langendam MW, Lewin S, Macdonald H, McFarlane E, Meerpohl J, Munn Z, Murad MH, Mustafa RA, Neumann I, Nieuwlaat R, Nowak A, Pardo JP, Qaseem A, Rada G, Righini M, Rochwerf B, Rojas-Reyes MX, Siegal D, Siemieniuk R, Singh JA, Skoetz N, Sultan S, Synnot A, Tugwell P, Turner A, Turner T, Venkatachalam S, Welch V, Wiercioch W. A Framework for the Development of Living Practice Guidelines in Health Care. *Annals of internal medicine*. 2022;175(8):1154-60.
5. Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, Buckley BS, Probyn K, Villanueva G, Henschke N, Bonnet H, Assi R, Menon S, Marti M, Devane D, Mallon P, Lelievre JD, Askie LM, Kredo T, Ferrand G, Davidson M, Riveros C, Tovey D, Meerpohl JJ, Grasselli G, Rada G, Hróbjartsson A, Ravaud P, Chaimani A, **Boutron I**. Efficacy and safety of COVID-19 vaccines. *The Cochrane database of systematic reviews*. 2022;12(12):Cd015477.
6. Hopewell S, **Boutron I**, Chan AW, Collins GS, de Beyer JA, Hróbjartsson A, Nejtgaard CH, Østengaard L, Schulz KF, Tunn R, Moher D. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. *Nat Med*. 2022;28(9):1740-3.
7. Jankowski S, **Boutron I**, Clarke M. Influence of the statistical significance of results and spin on readers' interpretation of the results in an abstract for a hypothetical clinical trial: a randomised trial. *BMJ open*. 2022;12(4):e056503.
8. Kapp P, Esmail L, Ghosn L, Ravaud P, **Boutron I**. Transparency and reporting characteristics of COVID-19 randomized controlled trials. *BMC Med*. 2022;20(1):363.
9. Kwakkenbos L, Carrier ME, Welling J, Levis B, Levis AW, Sauve M, Turner KA, Tao L, Aguila K, Carboni-Jiménez A, Cañedo-Ayala M, Harb S, van den Ende C, Hudson M, van Breda W, Nguyen C, **Boutron I**, Rannou F, Thombs BD, Mouthon L. Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial. *Trials*. 2022;23(1):994.
10. Kwakkenbos L, Carrier ME, Welling J, Turner KA, Cumin J, Pépin M, van den Ende C, Schouffoer AA, Hudson M, van Breda W, Sauve M, Mayes MD, Malcarne VL, Nielson WR, Nguyen C, **Boutron I**, Rannou F, Thombs BD, Mouthon L. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND). *PeerJ*. 2022;10:e13471.
11. Kwakkenbos L, Østbø N, Carrier ME, Nielson WR, Fedoruk C, Levis B, Henry RS, Pope J, Frech T, Gholizadeh S, Johnson SR, Piotrowski P, Jewett LR, Gordon J, Chung L, Bilsker D, Tao L, Turner KA, Cumin J, Welling J, Fortuné C, Leite C, Gottesman K, Sauvé M, Reyna TSR, Hudson M, Larche M, van Breda W, Suarez-Almazor ME, Bartlett SJ, Malcarne VL, Mayes MD, **Boutron I**, Mouthon L, Benedetti A, Thombs BD. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. *Pilot Feasibility Stud*. 2022;8(1):45.

12. Lobbé Q, Chavalarias D, Delanoë A, Ferrand G, Cohen-Boulakia S, Ravaud P, **Boutron I**. Toward an observatory of the evolution of clinical trials through phylomemy reconstruction: the COVID-19 vaccines example. *J Clin Epidemiol*. 2022;149:36-44.
13. Mavridis D, Nikolakopoulou A, Moustaki I, Chaimani A, Porcher R, **Boutron I**, Ravaud P. Considering multiple outcomes with different weights informed the hierarchy of interventions in network meta-analysis. *J Clin Epidemiol*. 2022.
14. Nguyen C, **Boutron I**, Roren A, Anract P, Beaudreuil J, Biau D, Boisdard S, Daste C, Durand-Zaleski I, Eschalié B, Gil C, Lefèvre-Colau MM, Nizard R, Perrodeau É, Rabetrano H, Richette P, Sanchez K, Zalc J, Coudeyre E, Rannou F. Effect of Prehabilitation Before Total Knee Replacement for Knee Osteoarthritis on Functional Outcomes: A Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(3):e221462.
15. Nguyen VT, Ravaud P, Tran VT, Young B, **Boutron I**. Patients' Perspectives on Transforming Clinical Trial Participation: Large Online Vignette-based Survey. *J Med Internet Res*. 2022;24(2):e29691.
16. Pellat A, **Boutron I**, Coriat R, Ravaud P. Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment. *Cancers (Basel)*. 2022;14(16).
17. Pellat A, **Boutron I**, Ravaud P. Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years. *Oncologist*. 2022;27(11):e849-e55.
18. Pellat A, **Boutron I**, Ravaud P. Availability of results of interventional studies assessing colorectal cancer from 2013 to 2020. *PloS one*. 2022;17(4):e0266496.
19. Pellat A, **Boutron I**, Ravaud P. Assessment of transparency and selective reporting of interventional trials studying colorectal cancer. *BMC Cancer*. 2022;22(1):278.
20. Pierre O, Riveros C, Charpy S, **Boutron I**. Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. *J Clin Epidemiol*. 2022;141:46-53.
21. Rozenberg P, Sénat MV, Deruelle P, Winer N, Simon E, Ville Y, Kayem G, Porcher R, Perrodeau É, Desbrière R, **Boutron I**. Evaluation of the usefulness of ultrasound measurement of the lower uterine segment before delivery of women with a prior cesarean delivery: a randomized trial. *Am J Obstet Gynecol*. 2022;226(2):253.e1-e9.
22. Stewart R, **Boutron I**, Akl EA. The Global Evidence Commission's report provided a wake-up call for the evidence community. *J Clin Epidemiol*. 2022.
23. Vo TT, Cashin A, Superchi C, Tu PHT, Nguyen TB, **Boutron I**, MacKinnon D, Vanderweele T, Lee H, Vansteelandt S. Quality assessment practice in systematic reviews of mediation studies: results from an overview of systematic reviews. *J Clin Epidemiol*. 2022;143:137-48.

2021

24. Egnell M, **Boutron I**, Péneau S, Ducrot P, Touvier M, Galan P, Buscail C, Porcher R, Ravaud P, Hercberg S, Kesse-Guyot E, Julia C. Randomised controlled trial in an experimental online supermarket testing the effects of front-of-pack nutrition labelling on food purchasing intentions in a low-income population. *BMJ Open*. 2021;11(2):e041196.
25. Ghannad M, Yang B, Leeftang M, Aldcroft A, Bossuyt PM, Schroter S, **Boutron I**. A randomized trial of an editorial intervention to reduce spin in the abstract's conclusion of manuscripts showed no significant effect. *J Clin Epidemiol*. 2021;130:69-77.
26. Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, Bollig C, Henschke N, Sguassero Y, Nejstgaard CH, Menon S, Nguyen TV, Ferrand G, Kapp P, Riveros C, Ávila C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, **Boutron I**. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2021;3(3):Cd013881.
27. Grégory J, Créquit P, Vilgrain V, **Boutron I**, Ronot M. Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. *JHEP Rep*. 2021;3(1):100196.
28. Imran M, Kwakkenbos L, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, **Boutron I**, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thoms BD. Methods and results used in the development of a consensus-driven extension to

- the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). *BMJ Open*. 2021;11(4):e049093.
29. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, Cravioto A, Rees H, Higgins JPT, **Boutron I**, Pan H, Gruber MF, Arora N, Kazi F, Gaspar R, Swaminathan S, Ryan MJ, Henao-Restrepo AM. Considerations in boosting COVID-19 vaccine immune responses. *Lancet*. 2021;398(10308):1377-80.
 30. Kwakkenbos L, Imran M, McCall SJ, McCord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DB, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, **Boutron I**, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, Thoms BD. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. *Bmj*. 2021;373:n857.
 31. Nguyen C, **Boutron I**, Roren A, Baron G, Pauwels C, Lefèvre-Colau MM, Poiraudreau S, Dupeyron A, Coudeyre E, Rannou F. Home-based cycling using connected ergometric bicycles for people with lumbar spinal stenosis (FLEXCAL): Protocol for a randomised trial. *Ann Phys Rehabil Med*. 2021;64(2):101351.
 32. Nguyen C, **Boutron I**, Zegarrra-Parodi R, Baron G, Alami S, Sanchez K, Daste C, Boisson M, Fabre L, Krief P, Krief G, Lefèvre-Colau MM, Rannou F. Effect of Osteopathic Manipulative Treatment vs Sham Treatment on Activity Limitations in Patients With Nonspecific Subacute and Chronic Low Back Pain: A Randomized Clinical Trial. *JAMA Intern Med*. 2021;181(5):620-30.
 33. Nguyen VT, Engleton M, Davison M, Ravaud P, Porcher R, **Boutron I**. Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. *BMC Med*. 2021;19(1):279.
 34. Nguyen VT, Rivière P, Ripoll P, Barnier J, Vuillemot R, Ferrand G, Cohen-Boulakia S, Ravaud P, **Boutron I**. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. *J Clin Epidemiol*. 2021;130:107-16.
 35. Nordlund J, Henry RS, Kwakkenbos L, Carrier ME, Levis B, Nielson WR, Bartlett SJ, Dyas L, Tao L, Fedoruk C, Nielsen K, Hudson M, Pope J, Frech T, Gholizadeh S, Johnson SR, Piotrowski P, Jewett LR, Gordon J, Chung L, Bilsker D, Levis AW, Turner KA, Cumin J, Welling J, Fortuné C, Leite C, Gottesman K, Sauve M, Rodríguez-Reyna TS, Larche M, van Breda W, Suarez-Almazor ME, Wurz A, Culos-Reed N, Malcarne VL, Mayes MD, **Boutron I**, Mouthon L, Benedetti A, Thoms BD. The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. *Trials*. 2021;22(1):856.
 36. Orkin AM, Gill PJ, Gherzi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, **Boutron I**, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. *Jama*. 2021;326(3):257-65.
 37. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Int J Surg*. 2021;88:105906.
 38. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *J Clin Epidemiol*. 2021;134:178-89.
 39. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting

- P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*. 2021;372:n71.
40. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev*. 2021;10(1):89.
 41. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med*. 2021;18(3):e1003583.
 42. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol*. 2021;134:103-12.
 43. Page MJ, Moher D, Bossuyt PM, **Boutron I**, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *Bmj*. 2021;372:n160.
 44. Paludan-Müller AS, Créquit P, **Boutron I**. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review. *BMC Med*. 2021;19(1):88.
 45. Pierre O, Riveros C, Charpy S, **Boutron I**. Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. *J Clin Epidemiol*. 2021;141:46-53.
 46. Rozenberg P, Sénat MV, Deruelle P, Winer N, Simon E, Ville Y, Kayem G, Porcher R, Perrodeau É, Desbrière R, **Boutron I**. Evaluation of the usefulness of ultrasound measurement of the lower uterine segment before delivery of women with a prior cesarean delivery: a randomized trial. *Am J Obstet Gynecol*. 2021.
 47. Vo TT, Cashin A, Superchi C, Tu PHT, Nguyen TB, **Boutron I**, McKinnon D, Vanderweele T, Lee H, Vansteelandt S. Quality assessment practice in systematic reviews of mediation studies: results from an overview of systematic reviews. *J Clin Epidemiol*. 2021.

2020

48. Blanco D, Schroter S, Aldcroft A, Moher D, **Boutron I**, Kirkham JJ, Cobo E. Effect of an editorial intervention to improve the completeness of reporting of randomised trials: a randomised controlled trial. *BMJ Open*. 2020;10(5):e036799.
49. **Boutron I**. Spin in Scientific Publications: A Frequent Detrimental Research Practice. *Ann Emerg Med*. 2020;75(3):432-4.
50. **Boutron I**, Chaimani A, Meerpohl JJ, Hróbjartsson A, Devane D, Rada G, Tovey D, Grasselli G, Ravaud P. The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. *Ann Intern Med*. 2020;173(12):1015-7.
51. **Boutron I**, Créquit P, Williams H, Meerpohl J, Craig JC, Ravaud P. Future of evidence ecosystem series: 1. Introduction Evidence synthesis ecosystem needs dramatic change. *J Clin Epidemiol*. 2020;123:135-42.
52. Carrier ME, Kwakkenbos L, Nielson WR, Fedoruk C, Nielsen K, Milette K, Pope J, Frech T, Gholizadeh S, Hummers L, Johnson SR, Piotrowski P, Jewett L, Gordon J, Chung L, Bilsker D, Turner KA, Cumin J, Welling J, Fortune C, Leite C, Gottesman K, Sauve M, Rodríguez-Reyna TS, Hudson M, Larche M, van Breda W, Suarez-Almazor ME, Bartlett SJ, Malcarne VL, Mayes MD, **Boutron I**, Mouthon L, Wigley F, Thombs BD. The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. *JMIR Res Protoc*. 2020;9(4):e16799.

53. Cohen JF, Korevaar DA, **Boutron I**, Gatsonis CA, Hopewell S, McInnes MDF, Moher D, von Elm E, Bossuyt PM. Reporting guidelines for journal and conference abstracts. *J Clin Epidemiol*. 2020;124:186-92.
54. Créquit P, **Boutron I**, Meerpohl J, Williams HC, Craig J, Ravaud P. Future of evidence ecosystem series: 2. current opportunities and need for better tools and methods. *J Clin Epidemiol*. 2020;123:143-52.
55. Glonti K, **Boutron I**, Moher D, Hren D. Journal editors' perspectives on the communication practices in biomedical journals: a qualitative study. *BMJ Open*. 2020;10(8):e035600.
56. Grégory J, Créquit P, Vilgrain V, Ronot M, **Boutron I**. Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported. *Eur Radiol*. 2020;30(10):5633-40.
57. Kirkham JJ, Penfold NC, Murphy F, **Boutron I**, Ioannidis JP, Polka J, Moher D. Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. *BMJ Open*. 2020;10(12):e041849.
58. Lundh A, **Boutron I**, Stewart L, Hróbjartsson A. What to do with a clinical trial with conflicts of interest. *BMJ Evid Based Med*. 2020;25(5):157-8.
59. Lundh A, Rasmussen K, Østengaard L, **Boutron I**, Stewart LA, Hróbjartsson A. Systematic review finds that appraisal tools for medical research studies address conflicts of interest superficially. *J Clin Epidemiol*. 2020;120:104-15.
60. Moustgaard H, Clayton GL, Jones HE, **Boutron I**, Jørgensen L, Laursen DRT, Olsen MF, Paludan-Müller A, Ravaud P, Savović J, Sterne JAC, Higgins JPT, Hróbjartsson A. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. *Bmj*. 2020;368:l6802.
61. Naidoo N, Nguyen VT, Ravaud P, Young B, Amiel P, Schanté D, Clarke M, **Boutron I**. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. *BMC Med*. 2020;18(1):6.
62. Oikonomidi T, **Boutron I**, Pierre O, Cabanac G, Ravaud P. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. *BMC Med*. 2020;18(1):402.
63. Østengaard L, Lundh A, Tjørnhøj-Thomsen T, Abdi S, Gelle MHA, Stewart LA, **Boutron I**, Hróbjartsson A. Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study. *Bmj*. 2020;371:m3764.
64. Page MJ, McKenzie JE, Bossuyt PM, **Boutron I**, Hoffmann T, Mulrow CD, Shamseer L, Moher D. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. *J Clin Epidemiol*. 2020;118:60-8.
65. Ravaud P, Créquit P, Williams HC, Meerpohl J, Craig JC, **Boutron I**. Future of evidence ecosystem series: 3. From an evidence synthesis ecosystem to an evidence ecosystem. *J Clin Epidemiol*. 2020;123:153-61.
66. Sentenac M, **Boutron I**, Draper ES, Kajantie E, Maier RF, Wolke D, Zeitlin J. Defining Very Preterm Populations for Systematic Reviews With Meta-analyses. *JAMA Pediatr*. 2020;174(10):997-9.
67. Speich B, Schroter S, Briel M, Moher D, Puebla I, Clark A, Maia Schlüssel M, Ravaud P, **Boutron I**, Hopewell S. Impact of a short version of the CONSORT checklist for peer reviewers to improve the reporting of randomised controlled trials published in biomedical journals: study protocol for a randomised controlled trial. *BMJ Open*. 2020;10(3):e035114.
68. Superchi C, Hren D, Blanco D, Rius R, Recchioni A, **Boutron I**, González JA. Development of ARCADIA: a tool for assessing the quality of peer-review reports in biomedical research. *BMJ Open*. 2020;10(6):e035604.
69. Turner RM, Rhodes KM, Jones HE, Higgins JPT, Haskins JA, Whiting PF, Hróbjartsson A, Caldwell DM, Morris RW, Reeves BC, Worthington HV, **Boutron I**, Savović J. Agreement was moderate between data-based and opinion-based assessments of biases affecting randomized trials within meta-analyses. *J Clin Epidemiol*. 2020;125:16-25.
70. Vo TT, Superchi C, **Boutron I**, Vansteelandt S. The conduct and reporting of mediation analysis in recently published randomized controlled trials: results from a methodological systematic review. *J Clin Epidemiol*. 2020;117:78-88.

71. Cabanac G, Oikonomidi T, **Boutron I**. Day-to-day discovery of preprint-publication links. *Scientometrics*. 2021;1-20.

2019

72. Atal I, Porcher R, **Boutron I**, Ravaud P. The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. *J Clin Epidemiol*. 2019;111:32-40.
73. Blanco D, Altman D, Moher D, **Boutron I**, Kirkham JJ, Cobo E. Scoping review on interventions to improve adherence to reporting guidelines in health research. *BMJ Open*. 2019;9(5):e026589.
74. **Boutron I**. Commentary on "Compliance of Randomized Controlled Trials Published in General Surgical Journals With the CONSORT 2010 Statement". *Ann Surg*. 2019;269(3):e28.
75. **Boutron I**. Cochrane systematic reviews: contributions and perspectives. *Joint Bone Spine*. 2019;86(3):289-91.
76. **Boutron I**, Haneef R, Yavchitz A, Baron G, Novack J, Oransky I, Schwitzer G, Ravaud P. Three randomized controlled trials evaluating the impact of "spin" in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit. *BMC Med*. 2019;17(1):105.
77. Chauvin A, Ravaud P, Moher D, Schriger D, Hopewell S, Shanahan D, Alam S, Baron G, Regnaud JP, Crequit P, Martinez V, Riveros C, Le Cleach L, Recchioni A, Altman DG, **Boutron I**. Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study. *BMC Med*. 2019;17(1):205.
78. Egnell M, **Boutron I**, Péneau S, Ducrot P, Touvier M, Galan P, Buscail C, Porcher R, Ravaud P, Hercberg S, Kesse-Guyot E, Julia C. Front-of-Pack Labeling and the Nutritional Quality of Students' Food Purchases: A 3-Arm Randomized Controlled Trial. *Am J Public Health*. 2019;109(8):1122-9.
79. Ghannad M, Olsen M, **Boutron I**, Bossuyt PM. A systematic review finds that spin or interpretation bias is abundant in evaluations of ovarian cancer biomarkers. *J Clin Epidemiol*. 2019;116:9-17.
80. Ghosn L, **Boutron I**, Ravaud P. Consolidated Standards of Reporting Trials (CONSORT) extensions covered most types of randomized controlled trials, but the potential workload for authors was high. *J Clin Epidemiol*. 2019;113:168-75.
81. Glonti K, **Boutron I**, Moher D, Hren D. Journal editors' perspectives on the roles and tasks of peer reviewers in biomedical journals: a qualitative study. *BMJ Open*. 2019;9(11):e033421.
82. Glonti K, Cauchi D, Cobo E, **Boutron I**, Moher D, Hren D. A scoping review on the roles and tasks of peer reviewers in the manuscript review process in biomedical journals. *BMC Med*. 2019;17(1):118.
83. Grolleau F, Collins GS, Smarandache A, Pirracchio R, Gakuba C, **Boutron I**, Busse JW, Devereaux PJ, Le Manach Y. The Fragility and Reliability of Conclusions of Anesthesia and Critical Care Randomized Trials With Statistically Significant Findings: A Systematic Review. *Crit Care Med*. 2019;47(3):456-62.
84. Nguyen VT, Benchoufi M, Young B, Ghosn L, Ravaud P, **Boutron I**. A scoping review provided a framework for new ways of doing research through mobilizing collective intelligence. *J Clin Epidemiol*. 2019;110:1-11.
85. Nguyen VT, Young B, Ravaud P, Naidoo N, Benchoufi M, **Boutron I**. Overcoming Barriers to Mobilizing Collective Intelligence in Research: Qualitative Study of Researchers With Experience of Collective Intelligence. *J Med Internet Res*. 2019;21(7):e13792.
86. Regnaud JP, Davergne T, Palazzo C, Roren A, Rannou F, **Boutron I**, Lefevre-Colau MM. Exercise programmes for ankylosing spondylitis. *Cochrane Database Syst Rev*. 2019;10(10):Cd011321.
87. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, **Boutron I**, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj*. 2019;366:l4898.
88. Superchi C, González JA, Solà I, Cobo E, Hren D, **Boutron I**. Tools used to assess the quality of peer review reports: a methodological systematic review. *BMC Med Res Methodol*. 2019;19(1):48.

2018

89. Bolvig J, Juhl CB, **Boutron I**, Tugwell P, Ghogomu EAT, Pardo JP, Rader T, Wells GA, Mayhew A, Maxwell L, Lund H, Bliddal H, Christensen R. Some Cochrane risk-of-bias items are not important in osteoarthritis trials: a meta-epidemiological study based on Cochrane reviews. *J Clin Epidemiol*. 2018;95:128-36.
90. **Boutron I**, Ravaud P. Misrepresentation and distortion of research in biomedical literature. *Proc Natl Acad Sci U S A*. 2018;115(11):2613-9.
91. Heim A, Ravaud P, Baron G, **Boutron I**. Designs of trials assessing interventions to improve the peer review process: a vignette-based survey. *BMC Med*. 2018;16(1):191.
92. Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, Heneghan C, Jefferson T, **Boutron I**, Stewart L. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. *Syst Rev*. 2018;7(1):117.
93. James A, Yavchitz A, Ravaud P, **Boutron I**. Node-making process in network meta-analysis of nonpharmacological treatment are poorly reported. *J Clin Epidemiol*. 2018;97:95-102.
94. Jefferson T, Doshi P, **Boutron I**, Golder S, Heneghan C, Hodkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. *BMJ Evid Based Med*. 2018;23(6):210-7.
95. Kwakkenbos L, Imran M, McCord KA, Sampson M, Fröbert O, Gale C, Hemkens LG, Langan SM, Moher D, Relton C, Zwarenstein M, Benchimol EI, **Boutron I**, Campbell MK, Erlinge D, Jawad S, Ravaud P, Rice DB, Sauve M, van Staa TP, Thabane L, Uher R, Verkooijen HM, Juszczak E, Thombs BD. Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. *BMJ Open*. 2018;8(8):e025266.
96. Kwakkenbos L, Juszczak E, Hemkens LG, Sampson M, Fröbert O, Relton C, Gale C, Zwarenstein M, Langan SM, Moher D, **Boutron I**, Ravaud P, Campbell MK, Mc Cord KA, van Staa TP, Thabane L, Uher R, Verkooijen HM, Benchimol EI, Erlinge D, Sauvé M, Torgerson D, Thombs BD. Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. *Res Integr Peer Rev*. 2018;3:9.
97. Page MJ, **Boutron I**, Hansen C, Altman DG, Hróbjartsson A. Assessing risk of bias in studies that evaluate health care interventions: recommendations in the misinformation age. *J Clin Epidemiol*. 2018;97:133-6.
98. Rozenberg P, Deruelle P, Sénat MV, Desbrière R, Winer N, Simon E, Ville Y, Kayem G, **Boutron I**. Lower Uterine Segment Trial: A pragmatic open multicenter randomized trial. *Gynecol Obstet Fertil Senol*. 2018;46(4):427-32.
99. Yordanov Y, Dechartres A, Atal I, Tran VT, **Boutron I**, Crequit P, Ravaud P. Avoidable waste of research related to outcome planning and reporting in clinical trials. *BMC Med*. 2018;16(1):87.

2017

100. Nguyen C, **Boutron I**, Rein C, Baron G, Sanchez K, Palazzo C, Dupeyron A, Tessier JM, Coudeyre E, Eschalier B, Forestier R, Roques-Latrille CF, Attal Y, Lefèvre-Colau MM, Rannou F, Poiraudreau S. Intensive spa and exercise therapy program for returning to work for low back pain patients: a randomized controlled trial. *Sci Rep*. 2017 Dec 20;7(1):17956.
101. James A, Yavchitz A, Ravaud P, **Boutron I**. Node making process in network meta-analysis of non-pharmacological treatment are poorly reported. *J Clin Epidemiol*. 2017 Nov 28. pii: S0895-4356(17)30772-2.
102. Haneef R, Yavchitz A, Ravaud P, Baron G, Oranksy I, Schwitzer G, **Boutron I**. Interpretation of health news items reported with or without spin: protocol for a prospective meta-analysis of 16 randomised controlled trials. *BMJ Open*. 2017 Nov 17;7(11):e017425.

103. Blanco D, Kirkham JJ, Altman DG, Moher D, **Boutron I**, Cobo E. Interventions to improve adherence to reporting guidelines in health research: a scoping review protocol. *BMJ Open*. 2017 Nov 16;7(11):e017551.
104. Sharp MK, Haneef R, Ravaud P, **Boutron I**. Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months. *BMJ Open*. 2017 Nov 3;7(11):e014503.
105. Glonti K, Cauchi D, Cobo E, **Boutron I**, Moher D, Hren D. A scoping review protocol on the roles and tasks of peer reviewers in the manuscript review process in biomedical journals. *BMJ Open*. 2017 Oct 22;7(10):e017468.
106. Nguyen C, **Boutron I**, Baron G, Coudeyre E, Berenbaum F, Poiraudeau S, Rannou F. Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial. *BMJ Open*. 2017 Sep 29;7(9):e017652.
107. Chauvin A, Moher D, Altman D, Schriger DL, Alam S, Hopewell S, Shanahan DR, Recchioni A, Ravaud P, **Boutron I**. A protocol of a cross-sectional study evaluating an online tool for early career peer reviewers assessing reports of randomised controlled trials. *BMJ Open*. 2017 Sep 15;7(9):e017462.
108. Vivot A, **Boutron I**, Béraud-Chaulet G, Zeitoun JD, Ravaud P, Porcher R. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. *Sci Rep*. 2017 Jul 31;7(1):6882.
109. Pussegoda K, Turner L, Garritty C, Mayhew A, Skidmore B, Stevens A, **Boutron I**, Sarkis-Onofre R, Bjerre LM, Hróbjartsson A, Altman DG, Moher D. Systematic review adherence to methodological or reporting quality. *Syst Rev*. 2017 Jul 19;6(1):131.
110. Ndounga Diakou LA, Ntoumi F, Ravaud P, **Boutron I**. Avoidable waste related to inadequate methods and incomplete reporting of interventions: a systematic review of randomized trials performed in Sub-Saharan Africa. *Trials*. 2017 Jul 5;18(1):291.
111. **Boutron I**, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann Intern Med*. 2017 Jul 4;167(1):40-47.
112. Pussegoda K, Turner L, Garritty C, Mayhew A, Skidmore B, Stevens A, **Boutron I**, Sarkis-Onofre R, Bjerre LM, Hróbjartsson A, Altman DG, Moher D. Identifying approaches for assessing methodological and reporting quality of systematic reviews: a descriptive study. *Syst Rev*. 2017 Jun 19;6(1):117.
113. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, **Boutron I**, Perrodeau E, Altman DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. *BMJ*. 2017 Jun 8;357:j2490. doi: 10.1136/bmj.j2490.
114. Nguyen C, **Boutron I**, Baron G, Sanchez K, Palazzo C, Benchimol R, Paris G, James-Belin É, Lefèvre-Colau MM, Beaudreuil J, Laredo JD, Béra-Louville A, Cotten A, Drapé JL, Feydy A, Ravaud P, Rannou F, Poiraudeau S. Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: A Randomized Trial. *Ann Intern Med*. 2017 Apr 18;166(8):547-556.
115. Baudard M, Yavchitz A, Ravaud P, Perrodeau E, **Boutron I**. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. *BMJ*. 2017 Feb 17;356:j448.

116. Ndounga Diakou LA, Ntoui F, Ravaud P, **Boutron I**. Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries. *J Clin Epidemiol*. 2017 Feb;82:29-36.e6.
117. Rannou F, **Boutron I**, Mouthon L, Sanchez K, Tiffreau V, Hachulla E, Thoumie P, Cabane J, Chatelus E, Sibilia J, Roren A, Berezne A, Baron G, Porcher R, Guillevin L, Ravaud P, Poiraudau S. Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. *Arthritis Care Res (Hoboken)*. 2017 Jul;69(7):1050-1059.
118. Lonjon G, Porcher R, Ergina P, Fouet M, **Boutron I**. Potential Pitfalls of Reporting and Bias in Observational Studies With Propensity Score Analysis Assessing a Surgical Procedure: A Methodological Systematic Review. *Ann Surg*. 2017 May;265(5):901-909.

2016

119. Hopewell S, **Boutron I**, Altman DG, Barbour G, Moher D, Montori V, Schriger D, Cook J, Gerry S, Omar O, Dutton P, Roberts C, Frangou E, Clifton L, Chiochia V, Rombach I, Wartolowska K, Ravaud P. Impact of a web-based tool (WebCONSORT) to improve the reporting of randomised trials: results of a randomised controlled trial. *BMC Med*. 2016 Nov 28;14(1):199.
120. Ndounga Diakou LA, Ntoui F, Ravaud P, **Boutron I**. Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries. *J Clin Epidemiol*. 2016 Nov 16.
121. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, **Boutron I**, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016 Oct 12;355:i4919.
122. Rannou F, **Boutron I**, Mouthon L, Sanchez K, Tiffreau V, Hachulla E, Thoumie P, Cabane J, Chatelus E, Sibilia J, Roren A, Berezne A, Baron G, Porcher R, Guillevin L, Ravaud P, Poiraudau S. A personalized physical therapy program or usual care for patients with systemic sclerosis: A randomized controlled trial. *Arthritis Care Res (Hoboken)*. 2016 Oct 1.
123. Buffel du Vaure C, Ravaud P, Baron G, Barnes C, Gilberg S, **Boutron I**. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. *BMJ Open*. 2016 Mar 22;6(3):e010119.
124. Ndounga Diakou LA, Trinquart L, Hróbjartsson A, Barnes C, Yavchitz A, Ravaud P, **Boutron I**. Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. *Cochrane Database Syst Rev*. 2016 Mar 10;3:MR000043. [Epub ahead of print] Review.
125. Porcher R, Leyrat C, Baron G, Giraudeau B, **Boutron I**. Performance of principal scores to estimate the marginal compliers causal effect of an intervention. *Stat Med*. 2016 Feb 28;35(5):752-67.
126. Yavchitz A, Ravaud P, Altman DG, Moher D, Hróbjartsson A, Lasserson T, **Boutron I**. A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity. *J Clin Epidemiol*. 2016 Feb 2.pii: S0895-4356(16)00057-3.
127. Baudart M, Ravaud P, Baron G, Dechartres A, Haneef R, **Boutron I**. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov. *BMC Med*. 2016 Jan 28;14(1):7.
128. Gaucher S, **Boutron I**, Marchand-Maillet F, Baron G, Douard R, Béthoux JP;AMBUPROG Group Investigators. Assessment of a Standardized Pre-Operative Telephone Checklist Designed to Avoid

2015

129. Hopewell S, **Boutron I**, Altman DG, Ravaud P. Deficiencies in the publication and reporting of the results of systematic reviews presented at scientific medical conferences. *J Clin Epidemiol*. 2015 Dec;68(12):1488-95.
130. Regnaud JP, Lefevre-Colau MM, Trinquart L, Nguyen C, **Boutron I**, Brosseau L, Ravaud P. High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoarthritis. *Cochrane Database Syst Rev*. 2015 Oct 29;10:CD010203.
131. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID, Ravaud P, **Boutron I**. Increasing value and reducing waste in biomedical research: who's listening? *Lancet*. 2015 Sep 25.
132. Haneef R, Lazarus C, Ravaud P, Yavchitz A, **Boutron I**. Interpretation of Results of Studies Evaluating an Intervention Highlighted in Google Health News: A Cross-Sectional Study of News. *PLoS One*. 2015 Oct 16;10(10):e0140889.
133. Lazarus C, Haneef R, Ravaud P, **Boutron I**. Classification and prevalence of spin in abstracts of non-randomized studies evaluating an intervention. *BMC Med Res Methodol*. 2015 Oct 13;15(1):85.
134. Porcher R, Leyrat C, Baron G, Giraudeau B, **Boutron I**. Performance of principal scores to estimate the marginal compliers causal effect of an intervention. *Stat Med*. 2015 Sep 17. doi: 10.1002/sim.6735.
135. Barnes C, **Boutron I**, Giraudeau B, Porcher R, Altman DG, Ravaud P. Impact of an online writing aid tool for writing a randomized trial report: the COBWEB (Consort-based WEB tool) randomized controlled trial. *BMC Med*. 2015 Sep 15;13:221.
136. Bourges JL, **Boutron I**, Monnet D, Brézin AP. Consensus on Severity for Ocular Emergency: The BASic SEverity Score for Common Ocular Emergencies [BaSe SCOrE]. *J Ophthalmol*. 2015;2015:576983.
137. Chauvin A, Ravaud P, Baron G, Barnes C, **Boutron I**. The most important tasks for peer reviewers evaluating a randomized controlled trial are not congruent with the tasks most often requested by journal editors. *BMC Med*. 2015 Jul 3;13:158.
138. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of research related to inadequate methods in clinical trials. *BMJ*. 2015 Mar 24;350:h809.
139. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, **Boutron I**, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015 Jun 2;162(11):777-84.
140. Cook JA, Elders A, Boachie C, Bassinga T, Fraser C, Altman DG, **Boutron I**, Ramsay CR, MacLennan GS. A systematic review of the use of an expertise-based randomised controlled trial design. *Trials*. 2015 May 30;16:241.
141. Hopewell S, **Boutron I**, Altman DG, Ravaud P. Deficiencies in the publication and reporting of the results of systematic reviews presented at scientific medical conferences. *J Clin Epidemiol*. 2015 Mar 28. pii: S0895-4356(15)00151-1.

142. Régnier-Rosencher E, **Boutron I**, Avril MF, Dupin N. Do anti-hypertensive renin-angiotensin system inhibitors contribute to the development of classical Kaposi sarcoma? *J Eur Acad Dermatol Venereol*. 2015 Apr 6.

2014

143. Vivot A, **Boutron I**, Ravaud P, Porcher R. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. *Genet Med*. 2014 Dec 18.
144. Yavchitz A, Ravaud P, Hopewell S, Baron G, **Boutron I**. Impact of adding a limitations section to abstracts of systematic reviews on readers' interpretation: a randomized controlled trial. *BMC Med Res Methodol*. 2014 Nov 24;14:123.
145. **Boutron I**, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. *J Clin Oncol*. 2014 Dec 20;32(36):4120-6.
146. Hansen JB, Juhl CB, **Boutron I**, Tugwell P, Ghogomu EA, Pardo Pardo J, Rader T, Wells GA, Mayhew A, Maxwell L, Lund H, Christensen R; Editorial Board of the Cochrane Musculoskeletal Group. Assessing bias in osteoarthritis trials included in Cochrane reviews: protocol for a meta-epidemiological study. *BMJ Open*. 2014 Oct 3;4(10):e005491.
147. Maruani A, **Boutron I**, Baron G, Ravaud P. Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial. *BMJ*. 2014 Sep 19;349:g5579.
148. Dechartres A, Altman DG, Trinquart L, **Boutron I**, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. *JAMA*. 2014 Aug 13;312(6):623-30.
149. Hubert D, Soubeiran L, Gourmelon F, Grenet D, Serreau R, Perrodeau E, Zegarrra-Parodi R, **Boutron I**. Impact of osteopathic treatment on pain in adult patients with cystic fibrosis--a pilot randomized controlled study. *PLoS One*. 2014 Jul 16;9(7):e102465.
150. Hopewell S, Collins GS, **Boutron I**, Yu LM, Cook J, Shanyinde M, Wharton R, Shamseer L, Altman DG. Impact of peer review on reports of randomised trials published in open peer review journals: retrospective before and after study. *BMJ*. 2014 Jul 1;349:g4145.
151. du Vaure CB, **Boutron I**, Perrodeau E, Ravaud P. Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of impact on general practitioners' confidence in conclusions, a three-arm randomized controlled trial. *BMC Med*. 2014 Apr 28;12(1):69.
152. Hoffmann TC, Glasziou PP, **Boutron I**, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014 Mar 7;348:g1687.
153. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Rasmussen JV, Hilden J, **Boutron I**, Ravaud P, Brorson S. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. *Int J Epidemiol*. 2014 Jan 21.
154. Glasziou P, Altman DG, Bossuyt P, **Boutron I**, Clarke M, Julious S, Michie S, Moher D, Wager E. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet*. 2014 Jan 7.
155. Cohen A, Assayag P, Boyer-Chatenet L, Cohen-Solal A, Perdrix C, Dalichampt M, Michel PL, Montalescot G, Ravaud P, Steg PG, **Boutron I**. An education program for risk factor management

after an acute coronary syndrome: a randomized clinical trial. *JAMA Intern Med.* 2014 Jan 1;174(1):40-8.

156. Lonjon G, **Boutron I**, Trinquart L, Ahmad N, Aim F, Nizard R, Ravaud P. Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. *Ann Surg.* 2014 Jan;259(1):18-25.

2013

157. Riveros C, Dechartres A, Perrodeau E, Haneef R, **Boutron I**, Ravaud P. Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals. *PLoS Med.* 2013 Dec;10(12):e1001566.
158. Houzé S, **Boutron I**, Marmorat A, Dalichampt M, Choquet C, Poilane I, Godineau N, Le Guern AS, Thellier M, Broutier H, Fenneteau O, Millet P, Dulucq S, Hubert V, Houzé P, Tubach F, Le Bras J, Matheron S. Performance of rapid diagnostic tests for imported malaria in clinical practice: results of a national multicenter study. *PLoS One.* 2013 Sep 30;8(9):e75486.
159. Turner L, **Boutron I**, Hróbjartsson A, Altman DG, Moher D. The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration. *Syst Rev.* 2013 Sep 23;2(1):79. doi: 10.1186/2046-4053-2-79
160. Cook A, Douet L, **Boutron I**. Descriptions of non-pharmacological interventions in clinical trials. *BMJ.* 2013 Sep 11
161. Hopewell S, **Boutron I**, Altman DG, Ravaud P. Incorporation of assessments of risk of bias of primary studies in systematic reviews of randomised trials: a cross-sectional study. *BMJ Open.* 2013 Aug 23;3(8)
162. Hróbjartsson A, **Boutron I**, Turner L, Altman DG, Moher D. Assessing risk of bias in randomised clinical trials included in Cochrane Reviews: the why is easy, the how is a challenge. *Cochrane Database Syst Rev.* 2013 Apr 30
163. Seegers V, Trinquart L, **Boutron I**, Ravaud P. Comparison of treatment effect estimates for pharmacological randomized controlled trials enrolling older adults only and those including adults: a meta-epidemiological study. *PLoS One.* 2013 May 28;8(5):e63677.
164. Dechartres A, Trinquart L, **Boutron I**, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. *BMJ.* 2013 Apr 24;346:f2304.
165. Baron G, Perrodeau E, **Boutron I**, Ravaud P. Reporting of analyses from randomized controlled trials with multiple arms: a systematic review. *BMC Med.* 2013 Mar 27;11:84.
166. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, **Boutron I**, Ravaud P, Brorson S. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. *CMAJ.* 2013 Mar 5;185(4):E201-11.
167. Benhamou M, Baron G, Dalichampt M, **Boutron I**, Alami S, Rannou F, Ravaud P, Poiraudou S. Development and validation of a questionnaire assessing fears and beliefs of patients with knee osteoarthritis: the Knee Osteoarthritis Fears and Beliefs Questionnaire (KOFBeQ). *PLoS One.* 2013;8(1):e53886.

2012

168. Yavchitz A, **Boutron I**, Bafeta A, Marroun I, Charles P, Mantz J, Ravaud P. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. *PLoS Med.* 2012 Sep;9(9):e1001308.

169. Tourabaly I, **Boutron I**, Nizard R, Ravaud P. ASSIST Applicability Scoring of Surgical trials. An Investigator-reported aSessment Tool. PLoS One. 2012;7(8):e42258. Epub 2012 Aug 15.
170. Pino C, **Boutron I**, Ravaud P. Inadequate description of educational interventions in ongoing randomized controlled trials. Trials. 2012 May 18;13(1):63.
171. Benhamou M, **Boutron I**, Dalichampt M, Baron G, Alami S, Rannou F, Ravaud P, Poiraudau S. Elaboration and validation of a questionnaire assessing patient expectations about management of knee osteoarthritis by their physicians: the Knee Osteoarthritis Expectations Questionnaire. Ann Rheum Dis. 2012 May 6.
172. Konrat C, **Boutron I**, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012;7(3):e33559.
173. Hopewell S, Ravaud P, Baron G, **Boutron I**. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012 Jun 22;344:e4178.
174. Pino C, **Boutron I**, Ravaud P. Outcomes in registered, ongoing randomized controlled trials of patient education. PLoS One. 2012;7(8):e42934.
175. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, **Boutron I**, Ravaud P, Brorson S. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012 Feb 27;344:e1119. doi: 10.1136/bmj.e1119.
176. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, **Boutron I**, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ. 2012 Feb 14;344:e813.
177. **Boutron I**, Ravaud P. Classification systems to improve assessment of risk of bias. J Clin Epidemiol. 2012 Mar;65(3):236-8.

2011

178. Hróbjartsson A, **Boutron I**. Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther. 2011 Nov;90(5):732-6. doi: 10.1038/clpt.2011.207. Epub 2011 Oct 12.
179. Dechartres A, **Boutron I**, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med. 2011 Jul 5;155(1):39-51.
180. Alami S, **Boutron I**, Desjeux D, Hirschhorn M, Meric G, Rannou F, Poiraudau S. Patients' and practitioners' views of knee osteoarthritis and its management: a qualitative interview study. PLoS One. 2011 May 5;6(5):e19634.
181. Boyer P, **Boutron I**, Ravaud P. Scientific production and impact of national registers: the example of orthopaedic national registers. Osteoarthritis Cartilage. 2011 Jul;19(7):858-63. Epub 2011 Mar 15. Review.
182. Ahmad N, **Boutron I**, Dechartres A, Durieux P, Ravaud P. Geographical representativeness of published and ongoing randomized controlled trials. The example of: Tobacco. consumption and HIV infection. PLoS One. 2011 Feb 9;6(2):e16878.

2010

183. **Boutron I**, Dutton S, Ravaud P, Altman D. Distorted Presentation in Reports of Randomized Controlled Trials with Statistically Nonsignificant Results for Primary Outcomes. *JAMA*. 2010 May 26;303(20):2058-64.
184. Alami S, **Boutron I**, Desjeux D, Hirschhorn M, Meric G, Rannou F, Poiraudau S. Patients' and practitioners' views of knee osteoarthritis and its management: a qualitative interview study. *PLoS One*. 2011 May 5;6(5):e19634.
185. Boyer P, **Boutron I**, Ravaud P. Scientific production and impact of national registers: the example of orthopaedic national registers. *Osteoarthritis Cartilage*. 2011 Jul;19(7):858-63. Epub 2011 Mar 15.
186. Glasziou P, Chalmers I, Altman DG, Bastian H, **Boutron I**, Brice A, Jamtvedt G, Farmer A, Ghera D, Groves T, Heneghan C, Hill S, Lewin S, Michie S, Perera R, Pomeroy V, Tilson J, Shepperd S, Williams JW. Taking healthcare interventions from trial to practice. *BMJ*. 2010 Aug 13;341:c3852.
187. Ahmad N, **Boutron I**, Dechartres A, Durieux P, Ravaud P. Applicability and generalisability of the results of systematic reviews to public health practice and policy: a systematic review. *Trials*. 2010 Feb 26;11(1):20
188. Lasocki S, Baron G, Driss F, Westerman M, Puy H, **Boutron I**, Beaumont C, Montravers P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. *Intensive Care Med*. 2010 Mar 6.

2009

189. Pibouleau L, **Boutron I**, Reeves BC, Nizard R, Ravaud P. Applicability and generalisability of published results of randomised controlled trials and non-randomised studies evaluating four orthopaedic procedures: methodological systematic review. *BMJ*. 2009 Nov 17;339:b4538.
190. Pitrou I, **Boutron I**, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. *Arch Intern Med*. 2009 Oct 26;169(19):1756-61.
191. Ergina PL, Cook JA, Blazeby JM, **Boutron I**, Clavien PA, Reeves BC, Seiler CM; Balliol Collaboration, Challenges in evaluating surgical innovation. *Lancet*. 2009 Sep 26;374(9695):1097-104.
192. Mathieu S, **Boutron I**, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. *JAMA*. 2009 Sep 2;302(9):977-84.
193. Rannou F, Dimet J, **Boutron I**, Baron G, Fayad F, Macé Y, Beaudreuil J, Richette P, Ravaud P, Revel M, Poiraudau S. Splint for base-of-thumb osteoarthritis: a randomized trial. *Ann Intern Med*. 2009 May 19;150(10):661-9.
194. Ethgen M, **Boutron I**, Steg PG, Roy C, Ravaud P. Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. *Trials*. 2009 May 4;10:29.
195. **Boutron I**, Ravaud P. Improving the reporting of clinical research. *Br J Surg*. 2009 May;96(5):449-50.
196. Ahmad N, **Boutron I**, Moher D, Pitrou I, Roy C, Ravaud P. Neglected external validity in reports of randomized trials: the example of hip and knee osteoarthritis. *Arthritis Rheum*. 2009 Mar 15;61(3):361-9.
197. Dechartres A, **Boutron I**, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. *J Clin Epidemiol*. 2009 Jul;62(7):695-702.
198. Ravaud P, Flipo RM, **Boutron I**, Roy C, Mahmoudi A, Giraudeau B, Pham T. ARTIST (osteoarthritis intervention standardized) study of standardised consultation versus usual care for patients with osteoarthritis of the knee in primary care in France: pragmatic randomised controlled trial. *BMJ*. 2009 Feb 23;338:b421. doi: 10.1136/bmj.b421.

199. Aparicio T, Navazesh A, **Boutron I**, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. *Crit Rev Oncol Hematol*. 2009 Sep;71(3):249-57.
200. de Monchy CC, Lepage L, **Boutron I**, Leye M, Detaint D, Hyafil F, Brochet E, Iung B, Vahanian A, Messika-Zeitoun D. Usefulness of the right parasternal view and non-imaging continuous-wave Doppler transducer for the evaluation of the severity of aortic stenosis in the modern era. *Eur J Echocardiogr*. 2009 May;10(3):420-4.
201. Leye M, Brochet E, Lepage L, Cuffe C, **Boutron I**, Detaint D, Hyafil F, Iung B, Vahanian A, Messika-Zeitoun D. Size-adjusted left ventricular outflow tract diameter reference values: a safeguard for the evaluation of the severity of aortic stenosis. *J Am Soc Echocardiogr*. 2009 May;22(5):445-51.

2008

202. **Boutron I**, Moher D, Altman DG, Schulz KF, Ravaud P for the CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. *Ann Intern Med*. 2008;148:295-309.
203. **Boutron I**, Moher D, Altman DG, Schulz KF, Ravaud P for the CONSORT Group. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. *Ann Intern Med*. 2008;148:W60-66.
204. **Boutron I**, Rannou F, Jardinaud-Lopez M, Meric G, Revel M, Poiraudreau S. Disability and quality of life of patients with knee or hip osteoarthritis in the primary care setting and factors associated with general practitioners' indication for prosthetic replacement within 1 year. *Osteoarthritis Cartilage*. 2008
205. Boutron I, Touizer C, Pitrou I, Roy C, Ravaud P. The VEPRO trial: a cross-over randomised controlled trial comparing 2 progressive lenses for patients with presbyopia. *Trials* 2008 Sep 19;9:54
206. Dechartres A, **Boutron I**, Nizard R, Poiraudreau S, Roy C, Baron G, Ravaud P, Ravaud JF. Knee arthroplasty: disabilities in comparison to the general population and to hip arthroplasty using a French national longitudinal survey. *PloS One* 2008 Jul 2;3(7):e2561
207. Biau DJ, Halm JA, Ahmadi H, Capello WN, Jeekel, **Boutron I**, Porcher R. I. Provider and center effect in multicenter randomized controlled trials of surgical specialties: an analysis on patient-level data. *Ann Surg*. 2008 May;247(5):892-8.
208. Biau DJ, Porcher R, **Boutron I**. The account for provider and center effects in multicenter interventional and surgical randomized controlled trials is in need of improvement: a review. *J Clin Epidemiol*. 2008

2007

209. **Boutron I**, Guittet L, Estellat C, Moher D, Hróbjartsson A, Ravaud P. "Methods of blinding in reports of randomized controlled trials assessing Non Pharmacological Treatments. A systematic review" Reporting Methods of Blinding in Randomized Trials Assessing Nonpharmacological Treatments. *PLoS Med*. 2007;4:e61.
210. **Boutron I**, Ravaud P, Nizard R. The design and assessment of prospective randomised, controlled trials in orthopaedic surgery. *J Bone Joint Surg Br*. 2007;89-B:858-863.
211. Dechartres A, **Boutron I**, Nizard R, Poiraudreau S, Roy C, Ravaud J. F, Ravaud P. Evolution of disability in adults with hip arthroplasty: a French national longitudinal study *Arthritis Rheum*. 2007;57:364-371.

212. Baron G, **Boutron I**, Giraudeau B, Ravaud P. Reporting of radiographic methods in randomized controlled trials assessing structural outcomes in rheumatic diseases. *Ann Rheum Dis*, 2007;66:651-657.
213. Rannou F, **Boutron I**, Jardinaud-Lopez M, Meric G, Revel M, Fermanian J, Poiraudau S. Should aggregate scores of the Medical Outcomes Study 36-item Short Form Health Survey be used to assess quality of life in knee and hip osteoarthritis? A national survey in primary care. *Osteoarthritis Cartilage*. 2007 Sep;15(9):1013-8
214. Rannou F, Ouanes W, **Boutron I**, et al. High-sensitivity C-reactive protein in chronic low back pain with vertebral end-plate modic signal changes. *Arthritis Rheum*. 2007;57:1311-1315.
215. Fourcade L, **Boutron I**, Moher D, Ronceray L, Baron G, Ravaud P. Development and evaluation of a pedagogical tool to improve understanding of a quality checklist: a randomised controlled trial. *PLoS Clin Trials*. 2007;2:e22

2006

216. **Boutron I**, Estellat C, Guittet L, Dechartres A, Sackett D, Hróbjartsson A, Ravaud P. Methods of blinding in reports of randomized controlled trials assessing Pharmacological Treatments. A systematic review. *PLoS Med*. 2006;3:e425.
217. Jacquier I, **Boutron I**, Moher D, Roy C, Ravaud P. The Reporting of Randomized Clinical Trials Using a Surgical Intervention is in Need of Immediate Improvement: A systematic review. *Ann Surg*, 2006;244:677-683.
218. Thabut G; Estellat C, **Boutron I**, Samama C-M; Ravaud P. Methodological issues in trials assessing primary prophylaxis of venous thromboembolism. *Eur Heart J*. 2006; 27: 227-236.
219. Ravaud P, **Boutron I**, Assessing the efficacy and safety of nonpharmacologic treatments for rheumatic diseases. *Nature Clinical Practice Rheumatology*, 2006; 2: 313-319. (review)

2005

220. **Boutron I**, Estellat C, Ravaud P. A review of blinding in randomized controlled trials found results inconsistent and questionable. *J Clin Epidemiol*. 2005; 58:1220-1226.
221. **Boutron I**, Moher D, Tugwell P, Giraudeau B, Poiraudau P, Nizard R, Ravaud P. A Checklist to Evaluate A Report of a NonPharmacological Trial (CLEAR NPT) was developed using consensus. *J Clin Epidemiol*. 2005; 58:1233-1240.
222. Ethgen M, **Boutron I**, Baron G, Sibilia J, Ravaud P. Reporting of harm in randomized controlled trials evaluating non-pharmacologic treatments for rheumatic disease. *Ann Intern Med*. 2005;143:20-5.
223. Baron G, **Boutron I**, Giraudeau B, Ravaud P. Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. *Arthritis Rheum*. 2005;52:1858-1865.

2004

224. **Boutron I**, Tubach F, Giraudeau B, Ravaud P. Blinding was judged more difficult to achieve and maintain in non-pharmacological than pharmacological trials. *J Clin Epidemiol*. 2004; 57:543-550.
225. **Boutron I**, Poiraudau S, Ravaud P, Baron G, Revel M, Nizard R, Dougados M, Ravaud J-F. Social and personal consequences of disability in adults with hip and knee arthroplasty. A French national community-based survey. *J Rheumatol*. 2004; 31:759-766.

2003

226. **Boutron I**, Tubach F, Giraudeau B, Ravaud P. Methodological differences in clinical trials evaluating non-pharmacological treatments and pharmacological treatments of hip and knee osteoarthritis. *JAMA*. 2003;290:1062-70.
227. **Boutron I**, Poiraudau S, Ravaud J-F, Baron G, Revel M, Nizard R, Dougados M, Ravaud P. Disability in adults with hip and knee arthroplasty. A French national community based survey *Ann Rheum Dis*. 2003;62:748-54.

Publications as ‘Collaborator’

1. Harb S, Peláez S, Carrier ME, Kwakkenbos L, Bartlett SJ, Hudson M, Mouthon L, Sauvé M, Welling J, Shrier I, Thombs BD. Barriers and facilitators to physical activity for people with scleroderma: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Arthritis Care Res (Hoboken)*. 2021.
2. Sommer SJ, Harel D, Kwakkenbos L, Carrier ME, Gholizadeh S, Gottesman K, Leite C, Malcarne VL, Thombs BD. Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *BMJ Open*. 2020;10(10):e037639.
3. Thombs BD, Kwakkenbos L, Carrier ME, Bourgeault A, Tao L, Harb S, Gagarine M, Rice D, Bustamante L, Ellis K, Duchek D, Wu Y, Bhandari PM, Neupane D, Carboni-Jiménez A, Henry RS, Krishnan A, Sun Y, Levis B, He C, Turner KA, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett SJ, Dyas L, Patten S, Varga J. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. *J Psychosom Res*. 2020;135:110132.
4. Becetti K, Kwakkenbos L, Carrier ME, Gordon JK, Nguyen JT, Mancuso CA, Mouthon L, Nguyen C, Rannou F, Welling J, Thombs BD, Spiera RF. Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. *J Rheumatol*. 2019;46(12):1605-13.
5. Harel D, Mills SD, Kwakkenbos L, Carrier ME, Nielsen K, Portales A, Bartlett SJ, Malcarne VL, Thombs BD. Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. *BMJ Open*. 2019;9(2):e024010.
6. Kwakkenbos L, Cumin J, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Rannou F, Welling J, Thombs BD. Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *BMJ Open*. 2019;9(10):e029542.
7. Moore G, Cambon L, Michie S, Arwidson P, Ninot G, Ferron C, Potvin L, Kellou N, Charlesworth J, Alla F. Population health intervention research: the place of theories. *Trials*. 2019;20(1):285.
8. Thabane L, Cambon L, Potvin L, Pommier J, Kivits J, Minary L, Nour K, Blaise P, Charlesworth J, Alla F. Population health intervention research: what is the place for pilot studies? *Trials*. 2019;20(1):309.
9. Azar M, Rice DB, Kwakkenbos L, Carrier ME, Shrier I, Bartlett SJ, Hudson M, Mouthon L, Poiraudau S, van den Ende CHM, Johnson SR, Rodriguez Reyna TS, Schouffoer AA, Welling J, Thombs BD.

- Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *Disabil Rehabil.* 2018;40(17):1997-2003.
10. Blanco D, Biggane AM, Cobo E. Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? *Trials.* 2018;19(1):80.
 11. Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL. Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. *Arthritis Care Res (Hoboken).* 2018;70(11):1646-52.
 12. Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier ME, Hudson M, van den Ende CHM, Schouffoer AA, Welling J, Sauvé M, Thombs BD. The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. *Clin Exp Rheumatol.* 2018;36 Suppl 113(4):88-94.
 13. Mills SD, Kwakkenbos L, Carrier ME, Gholizadeh S, Fox RS, Jewett LR, Gottesman K, Roesch SC, Thombs BD, Malcarne VL. Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. *Arthritis Care Res (Hoboken).* 2018;70(10):1557-62.

Letters to the editor

1. Nguyen VT, Superchi C, Boutron I. 2-Year outcome from two parallel randomized controlled trials. Reporting considerations. *Osteoarthritis Cartilage.* 2019;27(3):e3-e4. (letter).
2. Boutron I, Tubach F, Giraudeau B, Ravaud P. "Inappropriateness of randomised trials for complex phenomena: single trial is never enough evidence to base decisions on." *BMJ.* 2005 330:94 (letter).
3. Boutron I, Ravaud P. "Premature application of trial results to clinical practice." *JAMA.* 2003;290:3072. (letter).